Literature DB >> 25227524

Association between genetic polymorphisms of ACE & eNOS and diabetic nephropathy.

P Huo1, D Zhang, X Guan, Y Mei, H Zheng, X Feng.   

Abstract

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, with multiple genetic and environmental factors involving in its etiology. ACE and eNOS gene were considered to have important roles in the development and progression of DN. In this study, a case-control study was carried out to investigate the effects of 7 SNPs in ACE gene and 2 SNPs in eNOS gene in the development of DN in Northern China.7 SNPs including A240T, A2350G, A5466C, A2215G, T3892C, C1237T and C3409T of ACE gene and 2 SNPs (G894T and T786C) of eNOS gene were genotyped by polymerase chain reaction restriction fragment length polymorphism method. 431 type 2 diabetic patients with nephropathy (cases) were compared to 420 type 2 diabetic patients without nephropathy (controls) in the study. Data were analyzed by SPSS 17.0 and HaploView software. The frequency distribution of A2350G, 4 haplotyps in ACE gene and G894T in eNOS gene were demonstrated to be different between case and control groups significantly. Whereas other SNPs and haplotypes had no differences in two cohorts. The results revealed that variations of ACE and eNOS gene had association with DN, which indicated ACE and eNOS gene may play an important role in pathogenesis of DN in Northern Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25227524     DOI: 10.1007/s11033-014-3736-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

1.  Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population.

Authors:  Sui-Lung Su; Kuo-Cheng Lu; Yuh-Feng Lin; Yu-Juei Hsu; Pong-Ying Lee; Hsin-Yi Yang; Sen-Yeong Kao
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-12-06       Impact factor: 1.636

2.  Association of ACE gene haplotype with essential hypertension.

Authors:  M Saeed; A N Khan; S Siddiqui; K Saboohi; S O Ali; P M Frossard
Journal:  J Hum Hypertens       Date:  2004-12       Impact factor: 3.012

3.  Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy.

Authors:  E R Seaquist; F C Goetz; S Rich; J Barbosa
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

Review 4.  Pathogenic role of nitric oxide alterations in diabetic nephropathy.

Authors:  Sharma S Prabhakar
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

5.  Association of ACE ID and ACE G2350A polymorphism with increased blood pressure in persons exposed to different sound levels in Pakistan.

Authors:  Syed Kashif Nawaz; Shahida Hasnain
Journal:  Int Arch Occup Environ Health       Date:  2011-02-09       Impact factor: 3.015

6.  Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure.

Authors:  X Zhu; N Bouzekri; L Southam; R S Cooper; A Adeyemo; C A McKenzie; A Luke; G Chen; R C Elston; R Ward
Journal:  Am J Hum Genet       Date:  2001-03-27       Impact factor: 11.025

7.  ACE gene polymorphism and atherosclerotic lesion of carotid artery among offsprings of type 2 diabetes mellitus.

Authors:  Dyah Purnamasari; Budiman D Widjojo; Dono Antono; Meilani Syampurnawati
Journal:  Acta Med Indones       Date:  2012-04

8.  ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy.

Authors:  Tarunveer Singh Ahluwalia; Monica Ahuja; Taranjit Singh Rai; Harbir Singh Kohli; Anil Bhansali; Kamal Sud; Madhu Khullar
Journal:  DNA Cell Biol       Date:  2009-03       Impact factor: 3.311

9.  Association of eNOS Glu298Asp polymorphism with end-stage renal disease.

Authors:  Eisei Noiri; Hiroaki Satoh; Jun-ichi Taguchi; Sergey V Brodsky; Akihide Nakao; Yumiko Ogawa; Satomi Nishijima; Takehiko Yokomizo; Katsushi Tokunaga; Toshiro Fujita
Journal:  Hypertension       Date:  2002-10       Impact factor: 10.190

10.  Association of the genetic polymorphisms of the ACE gene and the eNOS gene with lupus nephropathy in northern Chinese population.

Authors:  X Li; J An; R Guo; Z Jin; Y Li; Y Zhao; F Lu; H Lian; P Liu; Y Zhao; X Jin
Journal:  BMC Med Genet       Date:  2010-06-14       Impact factor: 2.103

View more
  5 in total

1.  Association of ACE polymorphism and diabetic nephropathy susceptibility.

Authors:  Hongbo Ma; Che Yu; Rong Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy.

Authors:  Andi Marquardt; Moh'd Mohanad Al-Dabet; Sanchita Ghosh; Shrey Kohli; Jayakumar Manoharan; Ahmed ElWakiel; Ihsan Gadi; Fabian Bock; Sumra Nazir; Hongjie Wang; Jonathan A Lindquist; Peter Paul Nawroth; Thati Madhusudhan; Peter R Mertens; Khurrum Shahzad; Berend Isermann
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

3.  Correlation of Endothelial Nitric Oxide Synthase Gene Polymorphism (GG, TT and GT Genotype) with Proteinuria and Retinopathy in Type 2 Diabetic Patients.

Authors:  Ali Momeni; Morteza Hashemzadeh Chaleshtori; Saeed Saadatmand; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2016-02-01

4.  Identified single-nucleotide polymorphisms and haplotypes at 16q22.1 increase diabetic nephropathy risk in Han Chinese population.

Authors:  Li-Na Liao; Ching-Chu Chen; Fang-Yang Wu; Cheng-Chieh Lin; Jen-Hao Hsiao; Chwen-Tzuei Chang; Sharon L R Kardia; Tsai-Chung Li; Fuu-Jen Tsai
Journal:  BMC Genet       Date:  2014-10-31       Impact factor: 2.797

5.  Association of eNOS and MCP-1 Genetic Variants with Type 2 Diabetes and Diabetic Nephropathy Susceptibility: A Case-Control and Meta-Analysis Study.

Authors:  Priyanka Raina; Ruhi Sikka; Himanshu Gupta; Kawaljit Matharoo; Surinder Kumar Bali; Virinder Singh; Ajs Bhanwer
Journal:  Biochem Genet       Date:  2021-02-20       Impact factor: 1.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.